Cargando…
Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy
Tumor cells are particularly dependent on NAD(+) due to higher rates of metabolism, DNA synthesis and repair. Nicotinamide phosphoribosyltransferase inhibitors (NAMPTis) inhibit NAD(+) biosynthesis and represent promising new anti-cancer agents. However, clinical efficacy has been limited by toxicit...
Autores principales: | Cole, Jonathan, Guiot, Marie-Christine, Gravel, Michel, Bernier, Cynthia, Shore, Gordon C., Roulston, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652819/ https://www.ncbi.nlm.nih.gov/pubmed/29100430 http://dx.doi.org/10.18632/oncotarget.20840 |
Ejemplares similares
-
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation
por: Audrito, Valentina, et al.
Publicado: (2020) -
NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions
por: Wang, Niannian, et al.
Publicado: (2022) -
NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer
por: Li, Xiao-qin, et al.
Publicado: (2019) -
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology
por: Roulston, Anne, et al.
Publicado: (2015) -
NAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples
por: Duarte-Pereira, Sara, et al.
Publicado: (2014)